DSDejun Sun

Dejun Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dejun Sun has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Qingjin Meng

    Department of Neurology, Brain Hospital of Jilin Province, Siping, Jilin 136000, P.R. China

    3 shared publications
  • Qiuhui Chen

    Department of Neurology, The Second Hospital of Jilin University, Jilin University, Changchun, Jilin 130041, P.R. China

    3 shared publications
  • Wanxu Guo

    Department of Neurology, The Second Hospital of Jilin University, Jilin University, Changchun, Jilin 130041, P.R. China

    3 shared publications
  • Ying Zhang

    Department of Neurology, The Second Hospital of Jilin University, Jilin University, Changchun, Jilin 130041, P.R. China

    3 shared publications
  • Yizhi Zhang

    Department of Neurology, The Second Hospital of Jilin University, Jilin University, Changchun, Jilin 130041, P.R. China

    3 shared publications
  • Sumei Liu

    Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    Low-Dose Taxol Promotes Neuronal Axons Extension and Functional Recovery after Spinal Cord Injury

    by Baoguo Liu, Sumei Liu, Dejun Sun

    Axonal regeneration has been the research focus in the field of clinical treatment for spinal cord injury (SCI). The growth and extension of neuronal axons is a dynamic biological process mediated by the cytoskeleton, and microtubule plays an important role in axonal growth. Moderate stabilization of microtubule promotes axonal growth and eliminates various intra- and extracellular mechanisms that impede axonal regeneration. After SCI, the damaged axons rapidly form a growth cone, wherein the stability of tubulin decreases, impairing axonal regeneration. Taxol with proven clinical safety is commonly used as a broad-spectrum antitumor drug. Importantly, Taxol can promote axonal extension by enhancing and stabilizing the microtubule assembly. In our study, we systematically investigated the differentiation of neural stem cells (NSCs) in vitro and functional recovery in injured rats in vivo following Taxol treatment. Low-dose Taxol promoted differentiation of NSCs to neurons and significantly extended the axons in vitro. In vivo, Taxol promoted the expression of βIII-tubulin in the injured areas and motor function recovery after SCI. Low-dose Taxol is a promising clinical agent to promote axonal regeneration after SCI.


  • Open Access

    [Corrigendum] Grifola frondosa polysaccharides induce breast cancer cell apoptosis via the mitochondrial-dependent apoptotic pathway

    by Yizhi Zhang, Dejun Sun, Qingjin Meng, Wanxu Guo, Qiuhui Chen, Ying Zhang

    Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, in Fig. 3B on p. 1092, the western blots shown for 'Bax' in the MCF-7 group and 'Cleaved Caspase-8' in the MDA-MB-231 group were strikingly similar, such that these may have been the identical data re-used in the same figure. The authors have subsequently re‑examined their data, and realize that the Cleaved Caspase-8 blots were incorrectly used in Fig. 3B during the process of assembling this figure (i.e., the western blots were duplicated, and these were correctly shown as the data for Bax in the MCF-7 group). Furthermore, the authors have realized that the western blots selected for the Cleaved Caspase-3 experiment in the western blots shown in Fig. 5D on p. 1093 were not as clear as they could have been, and also requested that the data here be changed for those from one of the repeated experiments. Consequently, the revised versions of Figs. 3 and 5, containing the correct data for the Cleaved Caspase-8 blots in the MDA-MB-231 group in Fig. 3B and the replacement Cleaved Caspase-3 blots in Fig. 5C, are shown on the next page. These errors did not affect the major conclusions reported in the paper. All the authors agree to the publication of this corrigendum, and thank the Editor of International Journal of Molecular Medicine for allowing them the opportunity to publish this. The authors regret the error that went unnoticed during the compilation of the figures in question, and apologize to the readership for any confusion that this may have caused. [International Journal of Molecular Medicine 40: 1089-1095, 2017; DOI: 10.3892/ijmm.2017.3081].


  • Open Access

    Grifola frondosa polysaccharides induce breast cancer cell apoptosis via the mitochondrial-dependent apoptotic pathway

    by Yizhi Zhang, Dejun Sun, Qingjin Meng, Wanxu Guo, Qiuhui Chen, Ying Zhang

    Grifola frondosa, a type of food and medical fungus, has been shown to exhibit various pharmacological activities, including anticancer effects. As the most typical cancer diagnosed among female patients, breast cancer remains a huge concern threatening human health globally. In the present study, the anti-breast cancer effects of Grifola frondosa polysaccharides (GFPs) and the underlying mechanisms were investigated in MCF-7 and MDA-MB-231 cells, as well as in nude mice bearing MCF-7 tumor xenografts. GFPs exerted cytotoxic effects on the cells, as indicated by a decrease in cell viability, and an increase in the apoptototic rate, lactate dehydrogenase release and reactive oxygen species accumulation, inducing mitochondrial dysfunction. The increased expression of Bax, cleaved caspase-3 and caspase-8, and the reduced levels of B-cell lymphoma 2 (Bcl-2) and Bcl-extra large (Bcl‑xL) were observed in the cells incubated with GFPs and in the tumor tissues of the mice treated with GFPs. Moreover, the GFPs significantly suppressed the phosphorylation of AKT/glycogen synthase kinase-3β and extracellular signal-regulated kinases in a time-dependent manner. Finally, the inhibition of MCF-7 tumor xenograft growth further confirmed the anti-breast cancer effects of GFPs. All these findings revealed that GFPs induced human breast cancer cell apoptosis via the mitochondrial-dependent apoptotic pathway, and provide experimental evidence to support the use of Grifola frondosa as a potential treatment for breast cancer.


  • Open Access

    Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2

    by Zhiding Wang, Dejun Sun, Guojiang Chen, Ge Li, Shuaijie Dou, Renxi Wang, He Xiao, Chunmei Hou, Yan Li, Jiannan Feng, et al.

    T cell immunoglobulin mucin-3 (Tim-3) is an immune checkpoint inhibitor and its dysregulation has been related to T cell tolerance and many immune disorders, such as tumors and infection tolerance. However, the physiopathology roles of Tim-3 in innate immunity remain elusive. Here, we demonstrate that Tim-3 inhibits macrophage phagocytosis of L. monocytogenes by inhibiting the nuclear erythroid 2-related factor 2 (Nrf2) signaling pathway and increases bacterial burden. Tim-3 signaling promotes Nrf2 degradation by increasing its ubiquitination and, as a result, decreasing its nuclear translocation. CD36 and heme oxygenase-1 (HO-1), two downstream molecules in the Tim-3-Nrf2 signaling axis, are involved in the Tim-3- mediated immune evasion of L. monocytogenes both in vitro and in vivo. We here identified new mechanisms by which Tim-3 induces infection tolerance. By modulating the Tim-3 pathway, we demonstrate the feasibility of manipulating macrophage function as a potent tool for treating infectious diseases, such as Listeria infection.


  • Calcium channels contribute to albiflorin-mediated antinociceptive effects in mouse model

    by Yizhi Zhang, Dejun Sun, Qingjin Meng, Wanxu Guo, Qiuhui Chen, Ying Zhang


  • Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3

    by Miaonan Sun, Huichun Tang, Yan Gao, Xinxuan Dai, Yue Yuan, Chunmei Zhang, Dejun Sun

    Onconase is an RNase of the ribonuclease A superfamily that is purified from the Northern leopard frog (Rana pipiens). It targets several types of malignant tumors, digests cytoplasmic transfer RNA (tRNA), and causes tumor cell apoptosis. Onconase has been employed in clinical trials as an antitumor drug, and has revealed its valuable clinical activity in several types of tumors, particularly pleural mesothelioma. However, its inefficiency in targeting tumor cells and its non‑specific toxicity in normal tissues have diminished its clinical benefits. Furthermore, cyclization of the N-terminal glutamine residue (Gln), possesses more RNase activity than the structure of Met ahead of Glu in the N-terminal (99:1), which is more difficult for producing onconase by Pichia pastoris. Under the guidance of α-mating factor-pre (α-MF-pre) secretion signal, the secretion of the recombinant protein can reach a high level. In the present study, we constructed a constitutive expression vector for onconase-(DV3)2 (Onc-DV3) production in yeast Pichia pastoris with the GAP promoter, in which the Onc-DV3 gene is inserted downstream of the truncated Saccharomyces cerevisiae α-mating factor-pre (α-MF-pre) secretion signal. The immuno-RNase Onc-DV3 expressed a high level of production and bioactivity and possessed enhanced capability to deliver the Onc molecule to tumor cell monomeric counterparts. Notably, Onc-DV3 showed strong cytotoxicity to highly metastatic tumor cells, weak cytotoxicity to lowly metastatic tumor cells and no toxicity to normal cells. These results demonstrate that the specific toxicity to highly metastatic tumor cells has made Onc-DV3 a promising antitumor drug by using two copies of DV3 for the targeted delivery of onconase.


  • Open Access

    The Anti-Cancer Potency and Mechanism of a Novel Tumor-Activated Fused Toxin, DLM

    by Dejun Sun, Miaonan Sun, Wenhe Zhu, Zhiding Wang, Yuefei Li, Jie Ma

    Melittin, which acts as a membrane-disrupting lytic peptide, is not only cytotoxic to tumors, but also vital to normal cells. Melittin had low toxicity when coupled with target peptides. Despite significant research development with the fused toxin, a new fused toxin is needed which has a cleavable linker such that the fused toxin can release melittin after protease cleavage on the tumor cell surface. We describe a novel fused toxin, composed of disintegrin, uPA (urokinase-type plasminogen activator)-cleavable linker, and melittin. Disintegrin is a single strand peptide (73 aa) isolated from Gloydius Ussuriensis venom. The RGD (Arg-Gly-Asp) site of disintegrin dominates its interaction with integrins on the surface of the tumor cells. uPA is over-expressed and plays an important role in tumor cell invasiveness and metastatic progression. The DLM (disintegrin-linker-melittin) linker is uPA-cleavable, enabling DLM to release melittin. We compared binding activity of our synthesized disintegrin with native disintegrin and report that DLM had less binding activity than the native form. uPA-cleavage was evaluated in vitro and the uPA-cleavable linker released melittin. Treating tumors expressing uPA with DLM enhanced tumor cell killing as well as reduced toxicity to erythrocytes and other non-cancerous normal cells. The mechanism behind DLM tumor cell killing was tested using a DNA ladder assay, fluorescent microscopy, flow cytometry, and transmission electron microscopy. Data revealed tumor cell necrosis as the mechanism of cell death, and the fused DLM toxin with an uPA-cleavable linker enhanced tumor selectivity and killing ability.